ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals Inc.

In a report released yesterday, from Oppenheimer maintained a Buy rating on ARS Pharmaceuticals, with a price target of $35.00. The company’s share...

ARS Pharmaceuticals (SPRY) Gets a Buy from Oppenheimer

Ars Pharmaceuticals, Inc. (($SPRY)) announced an update on their ongoing clinical study. Study Overview: Ars Pharmaceuticals, Inc. is conducting a ...

Current Quarter	$-0.4	Next Quarter	$-0.44
Current Year	$-1.74	Next Year	$-1.25
QoQ Growth	-10.0%	YoY Growth	+28.2%
3Y EPS CAGR	+26.6%	Target Price	$27.83
Consensus	Buy	Upside	+266.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRY	$7.59	+12.78%	3.90M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRY	$7.59	+12.8%	3.90M
3
4
5
6

SPRY

SPRY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get ARS Pharmaceuticals Inc. Data in Excel

Get ARS Pharmaceuticals Inc. Data in Excel